Page 87 - Biomarkers for risk stratification and guidance in heart failure

Chapter 4
Berger et al. (n = 188)8
UPSTEP (n = 268)11
TIME-CHF (n = 622)14,17
Signal-HF (n = 252)13
PROTECT (n = 151)10
PRIMA (n = 345)9
Troughton et al. (n = 69)15
BATTLESCARRED (n = 242)12
Overall (n = 2137)
86
Table 1 Continued
ACE-inhibitor (n = 1976) ARB (n = 1976)
-Blocker (n = 1976) Spironolactone
1460 (74%) 401 (20%) 1443 (73%) 716 (36%) 1706 (86%) 1072 (50%)
202 (83%) 47 (19%) 131 (54%) 27 (11%) 232 (96%) 121 (50%)
69 (100%) 0 (0%)
5 (7%)
0 (0%)
255 (74%) na
63 (18%) na
284 (82%) na
186 (54%) na
333 (97%) na
174 (50%) 75 (50%)
130 (54%) (n = 242)
479 (77%) 102 (16%) 476 (77%) 234 (38%) 574 (92%) 310 (50%)
196 (73%) 95 (35%) 252 (94%) 151 (56%) 232 (87%) 140 (52%)
129 (69%) 39 (21%) 149 (79%) 82 (44%) 154 (82%) 92 (49%)
(n = 1976)
Loop diuretic (n = 1976)
36 (15%) (n = 242)
(NT-pro)BNP-guided therapy
127 (50%)
69 (100%) 33 (48%)
112 (46%) (n = 242)
Numbers are n (%) unless
* Percentage of those with known left ventricular ejection fraction (LVEF).
† BNP levels.
BMI, body mass index; CVI, cerebrovascular insult; TIA, transient ischemic attack; COPD, chronic obstructive pulmonary disease; PVD, peripheral vascular disease; NYHA, New York heart association classification; ACE, angiotensin-converting enzyme; ARB, angiotensin-II receptor blocker; (NT-pro)BNP, (N-terminal pro-)brain natriuretic peptide; na, not available.
otherwise indicated.
55 (23%) (n = 242)
146 (60%) (n = 242)